Status:
RECRUITING
Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients
Lead Sponsor:
University of Salamanca
Conditions:
Breast Neoplasms
Alopecia
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Chemotherapy-induced alopecia (CIA) significantly compromises body image in breast cancer patients, particularly when involving eyebrow and eyelash loss (madarosis). While scalp cooling devices are ro...
Detailed Description
Background: Chemotherapy-induced alopecia (CIA) is one of the most distressing adverse effects for breast cancer patients, particularly when involving eyebrow and eyelash loss (madarosis). While scalp...
Eligibility Criteria
Inclusion
- Female participants aged ≥18 years
- Newly diagnosed breast cancer (any stage)
- Scheduled to receive anthracycline- and/or taxane-based chemotherapy as first-line systemic treatment
- No prior history of antineoplastic treatment
- Willing and able to provide written informed consent
Exclusion
- Patients with recurrent disease who have received prior hormone therapy, chemotherapy, and/or immunotherapy
- Presence of alopecia prior to the initiation of cancer treatment
- History of cerebral radiotherapy
Key Trial Info
Start Date :
November 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06955702
Start Date
November 15 2023
End Date
August 31 2026
Last Update
May 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Marqués de Valdecilla
Santander, Cantabria, Spain, 39011
2
Hospital Universitario de Salamanca
Salamanca, Salamanca, Spain, 37007